Single-cell transcriptional signature-based drug repurposing and in vitro evaluation in colorectal cancer
Open Access
- 25 March 2024
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 24 (1) , 1-11
Abstract
Background: The need for intelligent and effective treatment of diseases and the increase in drug design costs have raised drug repurposing as one of the effective strategies in biomedicine. There are various computational methods for drug repurposing, one of which is using transcription signatures, especially single-cell RNA sequencing (scRNA-seq) data, which show us a clear and comprehensive view of the inside of the cell to compare the state of disease and health. Methods: In this study, we used 91,103 scRNA-seq samples from 29 patients with colorectal cancer (GSE144735 and GSE132465). First, differential gene expression (DGE) analysis was done using the ASAP website. Then we reached a list of drugs that can reverse the gene signature pattern from cancer to normal using the iLINCS website. Further, by searching various databases and articles, we found 12 drugs that have FDA approval, and so far, no one has reported them as a drug in the treatment of any cancer. Then, to evaluate the cytotoxicity and performance of these drugs, the MTT assay and real-time PCR were performed on two colorectal cancer cell lines (HT29 and HCT116). Results: According to our approach, 12 drugs were suggested for the treatment of colorectal cancer. Four drugs were selected for biological evaluation. The results of the cytotoxicity analysis of these drugs are as follows: tezacaftor (IC10 = 19 µM for HCT-116 and IC10 = 2 µM for HT-29), fenticonazole (IC10 = 17 µM for HCT-116 and IC10 = 7 µM for HT-29), bempedoic acid (IC10 = 78 µM for HCT-116 and IC10 = 65 µM for HT-29), and famciclovir (IC10 = 422 µM for HCT-116 and IC10 = 959 µM for HT-29). Conclusions: Cost, time, and effectiveness are the main challenges in finding new drugs for diseases. Computational approaches such as transcriptional signature-based drug repurposing methods open new horizons to solve these challenges. In this study, tezacaftor, fenticonazole, and bempedoic acid can be introduced as promising drug candidates for the treatment of colorectal cancer. These drugs were evaluated in silico and in vitro, but it is necessary to evaluate them in vivo.Keywords
Funding Information
- Shahrekord University of Medical Sciences (IR.SKUMS.REC.1397.293)
- Biotechnology Development Council of the Islamic Republic of Iran (grant No: 980201)
This publication has 40 references indexed in Scilit:
- Plasma MMP-1 Expression as a Prognostic Factor in Colon CancerJournal of Surgical Research, 2021
- Successful treatment with famciclovir for varicella zoster virus infection resistant to acyclovirJournal of Infection and Chemotherapy, 2021
- BCL-2 family deregulation in colorectal cancer: potential for BH3 mimetics in therapyApoptosis, 2020
- Drug repurposing to overcome resistance to various therapies for colorectal cancerCellular and Molecular Life Sciences, 2019
- Establishment of Patient-Derived Organoids and Drug Screening for Biliary Tract CarcinomaCell Reports, 2019
- Using the Connectivity Map to discover compounds influencing human osteoblast differentiationJournal of Cellular Physiology, 2017
- Colonoscopic screening shows increased early incidence and progression of adenomas in cystic fibrosisJournal of Cystic Fibrosis, 2016
- Increased expression of SOX4 is associated with colorectal cancer progressionTumor Biology, 2016
- The consensus molecular subtypes of colorectal cancerNature Medicine, 2015
- Twist1-Induced Invadopodia Formation Promotes Tumor MetastasisCancer Cell, 2011